LifeTech ScientificLFTSF 96 ROC (Joel Greenblatt) % is 33.11% as of Dec. 2025, which is 27% below its 10-year median of 45.55. GuruFocus rates LFTSF with a GF Score™ of 96/100 and a GF Value™ of $0.35. The stock has 4 warning signs investors should review. Among 839 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 65.79% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 33.11%.
The historical rank and industry rank for LifeTech Scientific's ROC (Joel Greenblatt) % or its related term are showing as below:
LFTSF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.77 Med: 45.55 Max: 57.36
Current: 16.91
During the past 13 years, LifeTech Scientific's highest ROC (Joel Greenblatt) % was 57.36%. The lowest was 15.77%. And the median was 45.55%.
LFTSF's ROC (Joel Greenblatt) % is ranked better than 65.79% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 4.13
vs LFTSF: 16.91
LifeTech Scientific's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -25.80% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
LifeTech Scientific ROC (Joel Greenblatt) % Related Terms
LifeTech Scientific ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFTSF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, LifeTech Scientific's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 33.11% mean?
LifeTech Scientific (LFTSF) has a ROC (Joel Greenblatt) % of 33.11% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on LifeTech Scientific and its competitors. This is 27% below median its historical median of 45.55. Over the past decade, LifeTech Scientific's ROC (Joel Greenblatt) % has ranged from 15.77 to 57.36. According to the industry distribution chart, LifeTech Scientific ranks #287 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 34.2%.
Is LifeTech Scientific's ROC (Joel Greenblatt) % too high?
LifeTech Scientific's current ROC (Joel Greenblatt) % of 33.11% is 27% below median its 10-year median of 45.55. Over the past 10 years, this metric has ranged from a low of 15.77 to a high of 57.36. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.13. LifeTech Scientific's value of 33.11% is 701.7% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #287 out of 839 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #287 out of 839 companies for ROC (Joel Greenblatt) %. This puts LifeTech Scientific in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.13. LifeTech Scientific's value of 33.11% is 701.7% above this benchmark. Historically, LifeTech Scientific's own ROC (Joel Greenblatt) % has ranged from 15.77 to 57.36 over the past decade. While the company's 10-year median is 45.55 vs. the industry median of 4.13, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current ROC (Joel Greenblatt) % of 33.11% is 701.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current ROC (Joel Greenblatt) % is 33.11%, which is 27% below median its own 10-year median of 45.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current ROC (Joel Greenblatt) % of 33.11%. The stock's GF Value™ is $0.35, compared to a current price of $0.23 — trading 33.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 33.11%, which is 27% below median its 10-year median of 45.55 and 701.7% above the Medical Devices & Instruments industry median of 4.13. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current ROC (Joel Greenblatt) % is 33.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 33.3% below its estimated GF Value™ of $0.35.
Key valuation signals for LFTSF:
ROC (Joel Greenblatt) %: 33.11% (27% below median its 10-year median of 45.55)
GF Value™: $0.35 vs. price of $0.23 (33.3% below fair value)
Industry Position: 701.7% above the Medical Devices & Instruments median (#287 of 839)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score
Get the complete analysis for LFTSF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
